Skip to main content
Clinical Trials/CTRI/2022/04/042044
CTRI/2022/04/042044
Not yet recruiting
未知

Clinical effectiveness of Concentrated Growth Factor and injectable bioceramic material compared to MTA as pulpotomy agent in Permanent Mature Molar with Symptomatic Irreversible Pulpitis- a randomized controlled clinical trial.

S B Divya0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
S B Divya
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
S B Divya

Eligibility Criteria

Inclusion Criteria

  • 1\)Patients with symptomatic Irreversible Pulpitis of age 18 to 40 years permanent mature molar teeth with symptomatic irreversible pulpitis
  • 2\)Both Maxillary and Mandibular molar teeth.
  • 3\) A clinical diagnosis consistent with irreversible pulpitis will be established in all cases based on a history of severe spontaneous lingering pain that could be reproduced by cold testing.
  • 4\)Teeth which are tender to percussion can be included but those with periapical lesions, resorption of root must be excluded.

Exclusion Criteria

  • 1\)Patients \< 18years of age.
  • 2\)Patients of age \> 40 years of age
  • 3\)Medically compromised patients
  • 4\)Pregnant and lactating women.
  • 5\)Patients undergoing fixed orthodontic therapy
  • 6\)Patients with facial deformity including cleft lip/palate.
  • 7\)Teeth with apical periodontitis.
  • 8\)Teeth with fracture or crack lines.
  • 9\)Teeth with abrasion on the same tooth.

Outcomes

Primary Outcomes

Not specified

Similar Trials